SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Trenutno se ispituje u fazi 2 ključnog ispitivanja, CART-ddBCMA je Arcellxova T-stanična terapija koja koristi novo sintetičko vezivo tvrtke, D-domenu. Kite i Arcellx zajednički će unaprijediti i komercijalizirati imovinu CART-ddBCMA u SAD-u, a Kite će komercijalizirati proizvod izvan SAD-a
CAR T-Cell terapija jedan je od revolucionarnih lijekova za određene vrste raka krvi. U tijeku je više od 750 kliničkim ispitivanjima in CAR T-Cell terapija u Kini Trenutno. Pacijenti koji se žele upisati mogu se javiti CancerFax linija za pomoć pacijentima na WhatsAppu + 91 96 1588 1588 ili e-poštom na adresu info@cancerfax.com.
O Arcellxu
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multipli mijelom (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk mijelodisplastični sindrom, initiated in the fourth quarter of 2022.
O zmaju
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
O naukama Gilead
Gilead Sciences, Inc. je biofarmaceutska tvrtka koja je težila i postigla otkrića u medicini više od tri desetljeća, s ciljem stvaranja zdravijeg svijeta za sve ljude. Tvrtka je predana unaprjeđenju inovativnih lijekova za prevenciju i liječenje bolesti opasnih po život, uključujući HIV, virusni hepatitis i rak. Gilead posluje u više od 35 zemalja diljem svijeta, sa sjedištem u Foster Cityju u Kaliforniji. Gilead Sciences kupio je Kite 2017.
